Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Harrison

Showing results (41-50 of 153) with videos related to

Pageof 16
Sort By:
Leukemia & Lymphoma|October 9, 2010
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathyRebecca Howman, Arti Thakerer, Matthew Pitman, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 8, 2025
Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell DyscrasiasMary Sartor, Thomas X Lemarchand, Luise Britz, et al.
Transplantation Proceedings|October 11, 2020
Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center ExperienceJaideep Vazirani, David Routledge, Greg I Snell, et al.
Cancer Epidemiology|November 17, 2023
Sunlight, vitamin D, vitamin D receptor polymorphisms, and risk of multiple myeloma: A systematic reviewSimon Cheah, Dallas R English, Simon J Harrison, et al.
British Journal of Haematology|June 25, 2015
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapyBenjamin W Teh, Simon J Harrison, Leon J Worth, et al.
Blood Reviews|March 4, 2014
Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infectionBenjamin W Teh, Simon J Harrison, Marc Pellegrini, et al.
Internal Medicine Journal|December 27, 2023
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registrySueh-Li Lim, Cameron Wellard, Elizabeth Moore, et al.
Internal Medicine Journal|September 20, 2018
Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologistsAbby P Douglas, Karin A Thursky, Leon J Worth, et al.
Oncology and Therapy|March 7, 2017
The Perspectives of Haematological Cancer Patients on Tissue BankingHeidi Turon, Amy Waller, Tara Clinton-McHarg, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantationShaun Fleming, Simon J Harrison, Piers Blombery, et al.
Pageof 16

Showing results (41-50 of 153) with videos related to

Sort By:
Pageof 16
Leukemia & Lymphoma|October 9, 2010
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathyRebecca Howman, Arti Thakerer, Matthew Pitman, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 8, 2025
Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell DyscrasiasMary Sartor, Thomas X Lemarchand, Luise Britz, et al.
Transplantation Proceedings|October 11, 2020
Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center ExperienceJaideep Vazirani, David Routledge, Greg I Snell, et al.
Cancer Epidemiology|November 17, 2023
Sunlight, vitamin D, vitamin D receptor polymorphisms, and risk of multiple myeloma: A systematic reviewSimon Cheah, Dallas R English, Simon J Harrison, et al.
British Journal of Haematology|June 25, 2015
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapyBenjamin W Teh, Simon J Harrison, Leon J Worth, et al.
Blood Reviews|March 4, 2014
Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infectionBenjamin W Teh, Simon J Harrison, Marc Pellegrini, et al.
Internal Medicine Journal|December 27, 2023
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registrySueh-Li Lim, Cameron Wellard, Elizabeth Moore, et al.
Internal Medicine Journal|September 20, 2018
Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologistsAbby P Douglas, Karin A Thursky, Leon J Worth, et al.
Oncology and Therapy|March 7, 2017
The Perspectives of Haematological Cancer Patients on Tissue BankingHeidi Turon, Amy Waller, Tara Clinton-McHarg, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantationShaun Fleming, Simon J Harrison, Piers Blombery, et al.
Pageof 16